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Abstract
Background: Severe pain and impairments in functioning are commonly reported for youth with juvenile
fibromyalgia. The prevalence and impact of pain in other diseases commonly managed in pediatric rheumatology
comparatively have been rarely systematically studied. The objective of the current study was to determine the
extent to which high levels of pain and functional limitations, and the strength of their association, are unique to
youth with juvenile primary fibromyalgia syndrome/JPFS) relative to other pediatric rheumatic diseases.
Methods: Using data from 7753 patients enrolled in the multinational Childhood Arthritis and Rheumatology
Research Alliance (CARRA) Legacy Registry, we compared the levels and association of pain and functional
limitations between youth with JPFS and those with other rheumatic diseases.
Results: Pain levels were rated highest among youth with JPFS (M = 6.4/10, SD = 2.4) and lowest for juvenile
dermatomyositis (M = 1.7/10, SD = 2.2), with pain significantly higher in the JPFS group than any other pediatric
rheumatic disease (effect sizes = .22 to 1.05). Ratings on measures of functioning and well-being also were
significantly worse for patients with JPFS than patients with any other rheumatic disease (effect sizes = .62 to 1.06).
The magnitude of association between pain intensity and functional disability, however, generally was higher in
other rheumatic diseases than in JPFS. Pain was most strongly associated with functional limitations in juvenile
dermatomyositis, juvenile idiopathic arthritis, and mixed connective tissue disease.
Conclusions: JPFS is unique among conditions seen in pediatric rheumatology with regard to ratings of pain and
disability. However, pain appears to be comparably or more highly associated with level of functional impairment in
other pediatric rheumatic diseases. Pain in childhood rheumatic disease thus would benefit from increased
prioritization for research and treatment.
Keywords: Fibromyalgia, Pediatric rheumatic disease, Pain, Functional disability, Registry

Background
Juvenile primary fibromyalgia syndrome (JPFS) affects
up to 6% of otherwise healthy children and commonly
leads to subspecialty evaluation with a pediatric rheumatology provider [1–3]. The primary symptom of JPFS is
widespread musculoskeletal pain that persists in the absence of an underlying inflammatory disease or other
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medical condition. In at least a subset of youth with
JPFS, pain is associated with significant and enduring
impairment in the ability to participate in usual activities
and maintain positive well-being [4–7]. Reducing this
functional impairment often is regarded as a primary
goal of treatment for JPFS. This treatment goal is based
in part on the clinical tenet that the perception of pain
often improves once functional ability is optimized [8].
Thus, a strong association between severity of functional
disability and pain in JPFS is assumed in treatment and
has been partly borne out in extant research.
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For other medical conditions commonly managed in
pediatric rheumatology, levels of impairment in functioning and well-being also can be substantial. For example, children with juvenile dermatomyositis (JDM),
systemic lupus erythematosus (SLE), or juvenile idiopathic arthritis (JIA) have significantly reduced scores on
measures of health-related quality of life (HRQOL) relative to healthy peers [9–12]. The prevalence and severity
of pain in most pediatric rheumatic diseases, however,
rarely has been systematically studied [13]. Consequently, the extent to which pain is associated with indices of functioning across pediatric rheumatic diseases is
largely unknown. Determining this would help inform
the conceptualization and comprehensive treatment of
JPFS and other pediatric rheumatic diseases.
Multi-site patient registries offer an optimal means of
comparing clinical data across conditions. Registries use
observational study methods to collect high quality data
in naturalistic clinical settings [14]. Data elements typically are specified consistently, captured uniformly across
sites, and are considered to accurately represent the clinical status of patients. For diseases with relatively low
prevalence in particular, multi-site registries can be instrumental in ensuring sufficient sample sizes to make
generalizable inferences from comparative observational
research.
For the current study, we used data from the Childhood Arthritis and Rheumatology Research Alliance
(CARRA) Legacy Registry to achieve the following aims:
(a) to quantify the occurrence and intensity of pain
across a representative sample of pediatric patients diagnosed either with a chronic idiopathic musculoskeletal
pain condition (JPFS) or another rheumatic disease; and
(b) to determine if the strength of relationship between
pain and functioning is unique to JPFS or comparable
across diseases seen in pediatric rheumatology. We hypothesized that levels of pain and disability, and the
magnitude of their association, would be uniquely high
among youth with JPFS relative to youth with other
rheumatic diseases.

Patients and methods
Study design

The study was an observational study comprising a
retrospective review of data. Data were originally obtained as part of the CARRA Legacy Registry for patients
who enrolled and had an initial assessment visit between
May 2010 and May 2014 (the time period of active registry recruitment for the CARRA Legacy Registry). The
CARRA Legacy Registry is the largest multi-site clinical
database of children and adolescents with a rheumatic
disease. Data from this registry thus are regarded to be
generalizable and ideal for comparing disease characteristics and/or outcomes across diagnoses.
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Participants and sites

Patients from 56 pediatric rheumatology centers in North
America contributed data to the CARRA Legacy Registry.
Conditions represented in this registry and included for
the current study comprised Juvenile Primary Fibromyalgia Syndrome (JPFS), mixed connective tissue disease
(MCTD), SLE, JDM, JIA, and central nervous system vasculitis. To be eligible for the registry, patients had to be
under the age of 18 years at the time of symptom onset
and under the age of 21 years at the time of giving consent
to participate. For the current study, we included children
and adolescents who were between the ages of 5–21 (inclusive) at the time of consent. For JPFS, patients needed
to meet American College of Rheumatology (ACR) criteria
(if age 18 and above) or Yunus and Masi criteria [15–17].
Established diagnostic criteria were applied for each of the
other pediatric rheumatic diseases.
Procedure

Recruitment of patients to participate in the registry was
conducted by site research coordinators during new or
follow-up outpatient rheumatology visits. Written informed consent and assent (for those above 9 years old)
was obtained for all patients agreeing to enroll in the
registry. Standardized case report forms were used for
data collection at each site. Data sources included medical chart review, physician assessment, and physician/
parent/patient completion of subjective measures. Data
recorded on the case report forms were manually entered into local databases by site coordinators. Entered
data were integrated into a centralized i2b2 data warehouse from which approved registry investigators could
request deidentified databases for study analyses [18].
Procedures for the CARRA Legacy Registry were approved by the Institutional Review Board at each participating site. The current study was approved by the
Institutional Review Board at Hackensack University
Medical Center.
Measures
Patient characteristics

Information on patient- or parent-reported demographics
(age, sex, race, ethnicity, and family household income),
diagnosis, date of symptom onset, date first seen by a
pediatric rheumatologist, body mass index, and family history of fibromyalgia and autoimmune disease was recorded
on standardized case report forms at the index visit.
Pain intensity

Patients ages 10 and above were asked to rate the average intensity of pain associated with his/her condition
over the past week using a 0–10 numeric rating scale,
with 0 being “no pain” and 10 being “very severe pain.”
The numeric rating scale is considered a well-established
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measure for measuring the presence and intensity of
pain in pediatric populations [19]. For children ages 5–9,
the Faces Pain Scale Revised was used to quantify selfreported pain intensity [20].
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functional measures. SPSS® software (IBM) version 24.0
was used for all analyses.

Results
Patient characteristics

Measures of functioning

The Childhood Health Assessment Questionnaire was
completed by patients or caregiver proxies (for children
younger than 10) as a measure of impact of disease on
daily functioning over the past week [21]. This questionnaire has eight categories: dressing and grooming, arising, eating, walking, hygiene, reach and grip. Item scores
range from 0 to 3, with higher scores indicating worse
functioning. Patients (or caregiver proxies for children
under 10) also completed two global ratings pertaining
to the patient’s general functioning and well-being [22].
On the first, patients/caregivers were asked to rate the
patient’s overall health on a 5-point scale (“excellent” to
“very poor”), with higher scores indicating poorer
health-related quality of life. On the second, patients
were asked to consider all the ways their condition affects them and then use a 0–10 scale (“very well” to
“very poor”) to rate how they are currently doing; higher
numbers indicate poorer overall well-being. Clinicians
also rated functional ability using the 4-point ACR functional class rating (1 = “able to perform usual activities
of daily living; 4 = “limited in ability to perform usual
self-care, vocational, and avocational activities”) [23].
Disease activity

The physician global assessment of disease activity
(MDGA) was used to quantify disease activity on a 0–10
numeric rating scale, with “0” representing “inactive disease” and “10” representing “very active disease.” [24]
Analyses

Descriptive statistics (frequency counts and percentages,
means or medians, and standard deviations) were used to
summarize data from index visits on patient characteristics, pain intensity, and indices of functional disability
across all conditions. Differences in baseline patient characteristics as a function of group (JPFS versus other
rheumatic diseases combined) were evaluated using correlations, chi-square analyses, or independent samples ttests as applicable. Omnibus general linear models were
used to compare groups (JPFS versus other rheumatic diseases combined) on pain severity and on each of the functioning measures. In these models, age and MDGA were
specified as covariates. If the overall test was significant,
the JPFS group was compared to each of the individual
rheumatic diseases included in the combined group. Effect
sizes for group differences are reported based on Cohen’s
d formula. Fisher’s r-to-z transformation was used to compare disease groups on the correlation between pain and

Data on patient characteristics for the cohort are presented
in Table 1. Across all conditions there were 7753 patients,
primarily female, with ages ranging from 5 to 21 years inclusive (M = 13.0, SD = 4.0). Of these, 201 were diagnosed
with JPFS and 7552 were diagnosed with another rheumatic
disease (Table 1). The patients with JPFS on average were
significantly older than other patients with rheumatic diseases at the time of the index visit (M = 15.5 versus 13.0), at
the time of reported symptom onset (M = 12.1 versus 8.3),
and at the time of the first visit to a rheumatologist (M =
13.7 versus 9.2). A significantly higher proportion of females were represented among patients with JPFS (84%)
than in other rheumatic diseases (72%). A significantly
higher proportion of patients with a reported family history
of fibromyalgia or autoimmune disease were represented
among patients with JPFS (18 and 45%, respectively) than
in other rheumatic disease (4 and 31%, respectively). Patients with JPFS on average had significantly greater body
mass index (M = 24.2 versus 21.2). There were no other significant differences in measured patient characteristics between the JPFS cohort and other rheumatic disease cohort.
Comparison of pain across conditions

Table 2 provides average pain ratings as a function of each
of the individual conditions included in the study. Nearly
all (97%) of youth with JPFS reported current pain. The
majority (69%) of patients having a condition other than
JPFS also reported current pain at the index visit, but this
proportion was significantly lower than that of the JPFS
group, χ2(1, 7753) = 72.15, p < .01. Reported intensity of
pain was significantly higher on average for patients with
JPFS than for patients with other rheumatic diseases (M =
6.4, SD = 2.4 versus M = 2.6, SD = 2.7; F (1, 7749) = 167.9,
p < .01. effect size = 1.49). Regardless of diagnosis, the
mean pain intensity scores reported at the index visit
spanned the entire range from 0 to 10. All conditions also
had at least some patients rating pain in the severe range
(> 7/10). The proportion of patients reporting severe pain
was significantly greater for those in the JPFS cohort relative to the other rheumatic diseases group (54.7% versus
11.7%), χ2(1, 7753) = 324.6, p < .01. Lowest pain ratings
were observed for the group of patients diagnosed with juvenile dermatomyositis (M = 1.7/10, SD = 2.2).
Comparison of functional disability across conditions

Table 2 also provides summary data on the functioning
measures by each of the individual conditions included
in the study. After adjusting for physician-rated disease
activity and age, ratings on measures of functioning were
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Table 1 Demographic data for the juvenile primary fibromyalgia syndrome cohort and other rheumatic disease cohort
Variable

Juvenile Primary Fibromyalgia
Syndrome Cohort
(n = 201)

Combined Rheumatic
Disease Cohort
(n = 7552)

Age (years)*

M = 15.5, SD = 2.2 (range 9–20)

M = 13.0, SD = 4.0 (range 5–21)

Sex*

84% female

72% female

Race

85% White

80% White

Ethnicity

8% Black/AA

10% Black/AA

2% Asian
1% American Indian or

3% Asian
1% American Indian or

Alaskan Native

Alaskan Native

4% Other

6% Other

17% Hispanic

13% Hispanic

Median family income interval

$75–$100,000

$50–$75,000

Age at symptom onset (years)*

M = 12.1, SD = 3.1 (range 2–18)

M = 8.3, SD = 4.7 (range 0.2–21)

Age at first rheumatologist visit (years)*

M = 13.7, SD = 2.8 (range 3–20)

M = 9.2, SD = 4.7 (range 0.2–21)

Body mass index*

M = 24.1, SD = 6.0 (range 13.7–50.7)

M = 21.2, SD = 5.8 (range 11.1–53.0)

Family history of fibromyalgia*

18% yes

4% yes

Family history of autoimmune disease*

45% yes

31% yes

*Significant group difference in mean or proportion, p < .05

significantly worse for patients with JPFS than for patients with all other rheumatic diseases combined (effect
sizes = .62 to 1.06). Specifically, patients with JPFS on
average had significantly worse adjusted scores on the
perceived well-being measure (M = 5.0 vs. 2.5, F (1,
7610) = 66.79, p < .01, effect size = .87), the CHAQ
(M = .76 vs. .36, F (1, 7749) = 18.68, p < .01. effect size =
.72), ACR functional class index (M = 1.6 versus M =
1.2, F (1, 7318) = 49.68, p < .01, effect size = .58), and the
HRQOL measure (M = 3.0 versus M = 2.2, F (1, 7595) =
50.90, p < .01, effect size = .92).

Relationship between pain and function

Table 3 displays the correlations between the measures
of pain and functioning by each individual condition. In
general, the relationship between level of pain and indicators of functional disability was significantly greater
for children with other rheumatic diseases relative to patients with JPFS. The relationship of CHAQ functional
disability scores to pain level was highest for patients
with MCTD, SLE, JDM, and JIA patients (rs = .44–.59).
The relationship between pain and ACR functional class
scores was significantly stronger for patients with JDM

Table 2 Means and standard deviations for pain and functioning measures by condition
Condition

Pain

HRQOL

Well-Being

ACR
Functional
Class

CHAQ

M

SD

M

SD

M

SD

M

SD

M

SD

JPFS
(n = 201)

6.36

2.43

3.00

.83

5.08

2.19

1.60

.80

.76

.56

JIA
(n = 5681)

2.69

2.66

2.15

.83

2.45

2.35

1.25

.54

.38

.54

SLE
(n = 987)

2.40

2.61

2.40

.83

2.70

2.47

1.24

.57

.26

.46

JDM
(n = 558)

1.66

2.21

2.21

.88

2.34

2.45

1.34

.76

.41

.67

Vasculitis (n = 187)

1.86

2.52

2.35

.89

2.56

2.42

1.27

.67

.27

.61

MCTD
(n = 139)

2.96

2.35

2.37

.74

2.83

2.39

1.30

.56

.35

.49

Note: Values shown are unadjusted means and standard deviations. Higher pain scores reflect more severe pain. Higher scores on other measures indicate more
severe impairments in functioning. JPFS = juvenile primary fibromyalgia syndrome; JIA = juvenile idiopathic arthritis; SLE = systemic lupus erythematosus; JDM =
juvenile dermatomyositis; MCTD = mixed connective tissue disease
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Table 3 Correlations between measures of pain and
functioning by condition
Condition

HRQOL Well-Being ACR Functional Class CHAQ

JPFS (n = 201)

.40*
*†

.62*
*†

.24*
*†

.34*

JIA (n = 5681)

.51

.71

.36

.54*†

SLE (n = 987)

.46*

.62*

.29*

.44*†

*

*

JDM (n = 558)

.48

.57

.44

.59*†

Vasculitis (n = 187)

.47*

.52*

.16*

.31*

*

*

MCTD (n = 139)

*†

.55

.67

*†

.33

.56*†

* p < .05 for correlation coefficient; † = correlation coefficient is significantly
different (p < .05) from the JPFS group based on Fisher r-to-z transformation
analysis. JPFS juvenile primary fibromyalgia syndrome, JIA juvenile idiopathic
arthritis, SLE systemic lupus erythematosus, JDM juvenile dermatomyositis,
MCTD mixed connective tissue disease

and JIA (r = .44 and r = .36) than for those with JPFS
(r = .24). For HRQOL, scores were significantly more
strongly related to pain level for youth with JIA and
MCTD (r = .51 and r = .55) compared to youth with JPFS
(r = .40). Finally, relative to youth with JPFS, there was a
significantly stronger relationship observed between pain
and well-being ratings for JIA (r = .62 vs. r = .71,
respectively).

Discussion
Patients with JPFS were found in this study to reliably
report both higher levels of pain and more impairment
in functioning than children with any other rheumatic
disease. The degree to which pain is associated with impairment in functioning and well-being, however, was
found to be variable across rheumatic conditions. Results
suggested in particular that the occurrence and level of
pain in patients with JIA, JDM, SLE, and MCTD is robustly linked to indicators of greater impairments in
functioning.
This study further confirms that severe pain and impairment in functioning is typical in youth with JPFS
who are seen in pediatric rheumatology clinics. This is a
common observation in research on youth with idiopathic chronic musculoskeletal pain [4, 6, 25, 26]. A distinguishing feature of the current study, however, is that
uniformly collected data were aggregated into a registry
from multiple sites across North America. Thus, results
are likely generalizable beyond the idiosyncrasies of a
particular region or practice. Further, we were able to
compare identical measures of pain and functioning
across conditions managed in pediatric rheumatology.
To our knowledge, such comparison has not been previously done. Results of these analyses suggest that levels
of pain and functional impairment on average are more
severe in JPFS than other conditions encountered in
pediatric rheumatology. Similar findings were reported
in a recent adult study comparing indices of HRQOL
across rheumatic diseases; fibromyalgia was second only

to rheumatoid arthritis in its impact on functioning [27].
There are multiple potential reasons for these findings.
Youth with JPFS often are likely to have comorbid symptoms of anxiety and depression, which can further augment pain perception and problems with functioning
and quality of life [6]. Pain in JPFS also is partly a function of “amplification” (or disordered regulation) of nociceptive input and is the primary symptom affecting
youth with JPFS; this is not necessarily the case in other
pediatric rheumatic diseases. Pain and impairments in
functioning in JPFS may also be difficult to significantly
modify with the resources available to most pediatric
rheumatologists. Alternatively, children with a rheumatic
disease may be more likely than youth with JPFS to
downplay or underreport problems with pain and functioning to their care team out of concern that reporting
such problems could lead to increased bothersome medical treatment.
The ability to compare the relationship between pain
and indicators of functioning in the current study facilitated some unique findings. Pain in JPFS has a relatively
well-established moderate association with functional
limitations [4]. Patients with inflammatory rheumatic
disease and connective tissue disorders (JIA, JDM, SLE,
and MCTD), however, were observed in our study to
have a comparatively stronger relationship between pain
and functional disability. Identifying similarities in the
manifestation of the disease process in these particular
rheumatic diseases may help explain this finding. For example, it may be that the quality and/or location of pain
experienced with these conditions is especially limiting
for participating in the physical activities typically
enjoyed by children and adolescents. Pain in these conditions, when high or enduring, may also result in aggressive disease-modifying treatments that have adverse
consequences for functioning. Alternatively, pain may
work synergistically with other disease symptoms (e.g.,
muscle weakness, arthritis) common in these conditions
to further augment existing functional impairment. In
the absence of further research, possible explanations remain speculative. Nevertheless, the results further establish the unique importance for assessing and treating
pain in pediatric rheumatology. Managing disease activity understandably is the central focus in treating
rheumatic disease [28]. Regardless of disease activity
level, however, we observed a relatively robust relationship between pain and functional disability across most
pediatric rheumatic diseases.
Use of data from the CARRA Legacy Registry enabled
an evaluation of clinically relevant research questions
that otherwise would have been difficult and costly to
conduct. This registry provided the infrastructure for secure collection, storage, and sharing of uniformly collected data from multiple informants for over 9000
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pediatric rheumatology patients [29]. Cross-condition
comparisons were made possible by having included
common data elements in the registry, supplemented by
data collection forms specific to each disease. Despite
these advantages, there also were limitations associated
with use of registry data for the current study. Measures
used to evaluate pain and functioning sacrificed comprehensiveness for efficiency and universality. The selected
measures (e.g., the CHAQ) unlikely fully captures the
nuances of pain and functional impairment for all conditions evaluated in the study. Patients enrolled in the
registry also were a “convenience sample” being treated
in pediatric rheumatology and were able to speak and
read English. Further, not all 56 clinical sites contributed
data on each condition in the registry; for example,
fewer than half of sites contributed data on patients with
JPFS. Patients in the fibromyalgia sample also were required to meet classification criteria commonly used in
research (American College of Rheumatology criteria if
> = 18 years old or Yunus and Masi diagnostic criteria if
< 18 years). Thus, although use of the registry facilitated
access to data from representative cohorts of patients,
there may still be limits on the generalizability of findings. Data for the current study also were collected at a
single occasion during any point of a patient’s disease
course. Levels and associations of the variables studied
may have varied had we evaluated them prospectively.

Conclusions
Results of the current study further confirm that pain
and impairment in indicators of functioning often are
severe in youth with JPFS but may be even more connected with one another in patients with other rheumatic diseases including JIA, JDM, SLE, and MCTD. Pain
appears to reliably relate to perceived impairments in
typical daily functioning and overall well-being across
these conditions. Historically pain has been less routinely assessed or targeted for treatment in many
pediatric rheumatic disease relative to more objective indicators of disease activity. Pain and optimal approaches
to minimize its impact also have been rarely studied in
several of the pediatric rheumatic diseases. However,
more routine incorporation of pain and other patientreported outcomes into patient registries in part is helping to address this [29–31]. Our findings emphasize that
pain across conditions commonly managed in pediatric
rheumatology would benefit from continued increased
prioritization in assessment, treatment and research.
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